This bill establishes a comprehensive regulatory framework for the production and administration of psilocybin in Iowa, introducing new provisions under Chapter 124F. It defines key terms such as "active psilocybin," "qualified medical psilocybin provider," and "psilocybin production establishment," and mandates the creation of a licensing board to oversee the licensing of production facilities and therapy providers. The bill outlines operational requirements, including the implementation of an inventory control system, security measures, and the necessity for agents to carry registration cards while handling psilocybin. It also emphasizes the importance of independent testing laboratories and establishes penalties for non-compliance, ensuring public safety and adherence to state laws.

Additionally, the bill includes provisions to protect patients using psilocybin from discrimination in medical care and employment, while clarifying that employers are not required to reimburse for psilocybin treatments. It mandates that qualified medical psilocybin providers complete specific continuing education requirements and outlines their responsibilities in patient assessments and safety protocols. The legislation also requires the department to conduct a study on the use of other psychedelic compounds for medical treatment, with findings due by January 1, 2027. Overall, the bill aims to create a structured and accountable system for the legal use of psilocybin in therapeutic contexts while ensuring compliance with state regulations.

Statutes affected:
Introduced: 124.401